V Ramos-Martín1, A Johnson1, J Livermore1, L McEntee1, J Goodwin1, S Whalley1, F Docobo-Pérez2, T W Felton3, W Zhao4, E Jacqz-Aigrain4, M Sharland5, M A Turner1, W W Hope6. 1. Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK. 2. Department of Microbiology, Universidad de Sevilla, Seville, Spain. 3. University Hospital of South Manchester NHS Foundation Trust, Manchester, UK. 4. Department of Paediatric Pharmacology and Pharmacogenetics, Hôpital Robert Debré, Paris, France. 5. Paediatric Infectious Diseases Unit, St George's Hospital, London, UK. 6. Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK william.hope@liverpool.ac.uk.
Abstract
OBJECTIVES: CoNS are the most common cause of neonatal late-onset sepsis. Information on the vancomycin pharmacokinetics/pharmacodynamics against CoNS is limited. The aim of this study was to characterize vancomycin pharmacokinetic/pharmacodynamic relationships for CoNS and investigate neonatal optimal dosage regimens. METHODS: A hollow fibre and a novel rabbit model of neonatal central line-associated bloodstream CoNS infections were developed. The results were then bridged to neonates by use of population pharmacokinetic techniques and Monte Carlo simulations. RESULTS: There was a dose-dependent reduction in the total bacterial population and C-reactive protein levels. The AUC/MIC and Cmax/MIC ratios were strongly linked with total and mutant resistant cell kill. Maximal amplification of resistance was observed in vitro at an fAUC/MIC of 200 mg · h/L. Simulations predicted that neonates <29 weeks post-menstrual age are underdosed with standard regimens with respect to older age groups. CONCLUSIONS: The AUC/MIC and Cmax/MIC ratios are the pharmacodynamic indices that best explain total and resistant cell kill in CoNS infection. This suggests that less-fractionated regimens are appropriate for clinical use and continuous infusions may be associated with increased risk of emergence of antimicrobial resistance. This study has provided the pharmacodynamic evidence to inform an optimized neonatal dosage regimen to take into a randomized controlled trial.
OBJECTIVES: CoNS are the most common cause of neonatal late-onset sepsis. Information on the vancomycin pharmacokinetics/pharmacodynamics against CoNS is limited. The aim of this study was to characterize vancomycin pharmacokinetic/pharmacodynamic relationships for CoNS and investigate neonatal optimal dosage regimens. METHODS: A hollow fibre and a novel rabbit model of neonatal central line-associated bloodstream CoNS infections were developed. The results were then bridged to neonates by use of population pharmacokinetic techniques and Monte Carlo simulations. RESULTS: There was a dose-dependent reduction in the total bacterial population and C-reactive protein levels. The AUC/MIC and Cmax/MIC ratios were strongly linked with total and mutant resistant cell kill. Maximal amplification of resistance was observed in vitro at an fAUC/MIC of 200 mg · h/L. Simulations predicted that neonates <29 weeks post-menstrual age are underdosed with standard regimens with respect to older age groups. CONCLUSIONS: The AUC/MIC and Cmax/MIC ratios are the pharmacodynamic indices that best explain total and resistant cell kill in CoNS infection. This suggests that less-fractionated regimens are appropriate for clinical use and continuous infusions may be associated with increased risk of emergence of antimicrobial resistance. This study has provided the pharmacodynamic evidence to inform an optimized neonatal dosage regimen to take into a randomized controlled trial.
Authors: Vincent H Tam; Arnold Louie; Mark R Deziel; Weiguo Liu; George L Drusano Journal: Antimicrob Agents Chemother Date: 2006-11-20 Impact factor: 5.191
Authors: Barbara J Stoll; Nellie I Hansen; Edward F Bell; Seetha Shankaran; Abbot R Laptook; Michele C Walsh; Ellen C Hale; Nancy S Newman; Kurt Schibler; Waldemar A Carlo; Kathleen A Kennedy; Brenda B Poindexter; Neil N Finer; Richard A Ehrenkranz; Shahnaz Duara; Pablo J Sánchez; T Michael O'Shea; Ronald N Goldberg; Krisa P Van Meurs; Roger G Faix; Dale L Phelps; Ivan D Frantz; Kristi L Watterberg; Shampa Saha; Abhik Das; Rosemary D Higgins Journal: Pediatrics Date: 2010-08-23 Impact factor: 7.124
Authors: A Ahmed; H Jafri; I Lutsar; C C McCoig; M Trujillo; L Wubbel; S Shelton; G H McCracken Journal: Antimicrob Agents Chemother Date: 1999-04 Impact factor: 5.191
Authors: B J Stoll; T Gordon; S B Korones; S Shankaran; J E Tyson; C R Bauer; A A Fanaroff; J A Lemons; E F Donovan; W Oh; D K Stevenson; R A Ehrenkranz; L A Papile; J Verter; L L Wright Journal: J Pediatr Date: 1996-07 Impact factor: 4.406
Authors: Tawanda Gumbo; Arnold Louie; Mark R Deziel; Linda M Parsons; Max Salfinger; George L Drusano Journal: J Infect Dis Date: 2004-09-24 Impact factor: 5.226
Authors: Thomas P Lodise; Nimish Patel; Ben M Lomaestro; Keith A Rodvold; George L Drusano Journal: Clin Infect Dis Date: 2009-08-15 Impact factor: 9.079
Authors: Michael N Neely; Lauren Kato; Gilmer Youn; Lironn Kraler; David Bayard; Michael van Guilder; Alan Schumitzky; Walter Yamada; Brenda Jones; Emi Minejima Journal: Antimicrob Agents Chemother Date: 2018-01-25 Impact factor: 5.191
Authors: Nicola Farrington; Laura McEntee; Adam Johnson; Jennifer Unsworth; Christopher Darlow; Ana Jimenez-Valverde; Christoph Hornik; Rachel Greenberg; Julie Schwartz; Shampa Das; William Hope Journal: Antimicrob Agents Chemother Date: 2022-03-22 Impact factor: 5.938
Authors: Timothy M Rawson; Esmita Charani; Luke S P Moore; Mark Gilchrist; Pantelis Georgiou; William Hope; Alison H Holmes Journal: Ther Drug Monit Date: 2018-06 Impact factor: 3.681
Authors: Christopher A Darlow; Fernando Docobo-Perez; Nicola Farrington; Adam Johnson; Laura McEntee; Jennifer Unsworth; Ana Jimenez-Valverde; Silke Gastine; Ruwanthi Kolamunnage-Dona; Renata M A de Costa; Sally Ellis; François Franceschi; Joseph F Standing; Mike Sharland; Michael Neely; Laura Piddock; Shampa Das; William Hope Journal: Antimicrob Agents Chemother Date: 2021-06-17 Impact factor: 5.191
Authors: Walter M Yamada; Michael N Neely; Jay Bartroff; David S Bayard; James V Burke; Mike van Guilder; Roger W Jelliffe; Alona Kryshchenko; Robert Leary; Tatiana Tatarinova; Alan Schumitzky Journal: Pharmaceutics Date: 2020-12-30 Impact factor: 6.321
Authors: Lorrene A Buckley; Smita Salunke; Karen Thompson; Gerri Baer; Darren Fegley; Mark A Turner Journal: Int J Pharm Date: 2017-07-17 Impact factor: 5.875
Authors: T M Rawson; D O'Hare; P Herrero; S Sharma; L S P Moore; E de Barra; J A Roberts; A C Gordon; W Hope; P Georgiou; A E G Cass; A H Holmes Journal: J Antimicrob Chemother Date: 2018-04-01 Impact factor: 5.790
Authors: Louise F Hill; Mark A Turner; Irja Lutsar; Paul T Heath; Pollyanna Hardy; Louise Linsell; Evelyne Jacqz-Aigrain; Emmanuel Roilides; Mike Sharland Journal: Trials Date: 2020-04-15 Impact factor: 2.279